Insulin TDD | V-Go®

V-Go: Proven Effective Regardless of Patient’s Insulin Dose

Patients prescribed ≥100 U/day (100 to 280 Units/day) saw significant A1c and insulin reductions₄

clinical data chart

effect on glycemic control

Methods: Electronic medical records were queried to identify patients switched from previous insulin therapy to insulin delivery with V-Go. 104 patients were stratified by moderate baseline insulin doses (<100 U/day) or high baseline insulin doses (≥100 U/day)(n=38) and compared using TDD U/day and U/kg. A1c and average prescribed insulin dosing were collected at baseline and for 2 follow-up A1c results on V-Go (the VALIDATE study). TDD=total daily dose.

References: 4. Lajara R, Nikkel C. Poster: Using V-Go wearable insulin delivery device in patients prescribed high insulin doses: a comparison of clinical results between high and moderate insulin dose groups. Presented at: the Diabetes Technology Meeting, Bethesda MD. October 2015.

Important Risk Information

If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.

Insulin TDDV-Go® Reduces Daily Insulin Dose Requirements

V-Go: Proven Effective Regardless of Patient’s Insulin Dose

Important Risk Information